Fri, Nov 20, 2026中文About
Filings today 284 / Covered 15
Source: TDnet timely disclosures
Updated 11/20 20:30M&A / TOB 20 Guidance 7 Buybacks 11 Dividends 4 Capital 12 Earnings 16 People 3

Atla Group to buy 35% of REMED JAPAN for ¥78.077 million in new shares

Tue, Nov 17, 2026 15:30 JST Atla Group Co., Ltd. (6029.T) Services 中文

Atla Group Co., Ltd. (6029) said on Nov. 17 its board approved subscribing to 156,154 new shares of REMED JAPAN Co., Ltd. for ¥78.077 million, taking 35% of the voting rights and making it an equity-method affiliate.

Acquisition cost¥78.077 million
Shares acquired156,154 shares (35% of voting rights)
Call option16% (to 51% if exercised)
Signing and paymentAround early December 2026

REMED JAPAN, based in Tokyo's Chuo Ward and headed by Lee Geun-yong, sells products in Japan for its parent, KOSDAQ-listed Remed Co., Ltd. (302550), under an exclusive distribution agreement covering all Remed products. Atla Group signed a term sheet with both companies the same day.

Atla Group signed a memorandum of understanding with Remed on April 21, 2026. Remed makes non-invasive magnetic and shockwave treatment devices, including transcranial magnetic stimulation (TMS), neuromuscular magnetic stimulation (NMS) and extracorporeal shockwave therapy (ESWT) units. Atla Group plans to offer them through the network of about 3,000 clinics using its A-COMS platform for acupuncture and bonesetting clinics, and called the deal its first new-business investment under its growth strategy.

The capital increase lifts REMED JAPAN's outstanding shares to 446,154 from 290,000. Each side will nominate two of four directors, and Atla Group will appoint the auditor. All proceeds will go to working capital and marketing, not to early repayment of loans from Remed.

Item (¥ thousand)FY Dec. 2024FY Dec. 2025
Sales155,143132,895
Operating loss43,82439,639
Net loss45,95737,499
Net assets66,33928,839

Atla Group will also obtain a call option to buy a further 16% from Remed, priced on an EBITDA-multiple basis. Exercise would raise its stake to 51% and make REMED JAPAN a consolidated subsidiary; the company said it does not currently plan to go beyond 51%.

Next steps: signing of the definitive agreements and payment are scheduled for around early December 2026. The option can be exercised during a set period after REMED JAPAN's results for the year ending December 2028 are finalized.


Original filings
Related